Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
- |
Employees |
- |
Revenues (TTM) (Millions $) |
0 |
Net Income (TTM) (Millions $) |
-2 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
0 |
Mabvax Therapeutics Holdings, Inc.
Mabvax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company that is focused on the development of targeted immunotherapies for the treatment of cancer. The company utilizes its proprietary antibody discovery platform to identify and develop novel monoclonal antibodies that are designed to selectively target and treat specific types of cancer cells. Mabvax's approach involves using the body's immune system to recognize and attack cancer cells, potentially providing more precise and effective treatments. Their lead product candidate, MVT-5873, is currently being evaluated in clinical trials for the treatment of pancreatic and other forms of cancer. Mabvax Therapeutics Holdings, Inc. is headquartered in San Diego, California, and is dedicated to advancing the field of immunotherapy to combat cancer.
|